PyramIDH

A Phase 3, Multicenter, Open Label, Randomized, Non-comparative Two-arm Study of Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Adult Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an Isocitrate Dehydrogenase-1 (IDH1) Mutation (PyramIDH Study)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 3
Enrollment
48 patients (estimated)
Sponsors
Institut de Recherches Internationales Servier
Collaborators
Servier Bio-Innovation LLC
Tags
Isocitrate Dehydrogenase 1 (IDH1) Inhibitor, Randomization
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
2062
NCT Identifier
NCT06465953

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.